Diffuse Large B Cell Lymphoma: ASCO Tumor Boards

Product ID : DCLTB16
Price: $15.00
You will receive a link to your product from customerservice@asco.org within 1 hour of purchase confirmation. Shipping charges do not apply to digital products.
E-mail to a friend



This is a case-based activity that presents two cases of diffuse large B cell lymphoma (DLBCL), one is a 48-year-old man with a pancreatic head mass found to be CD10, CD20, and CD19 positive with kappa light chain restriction and the other a discussion of 69-year-old woman with CD10 positive DLBCL.


 At the end of this course, participants should be able to:

  • Describe the heterogeneity of Diffuse Large B Cell Lymphoma
  • Explain the prognostic impact of cell of origin in Diffuse Large B Cell Lymphoma
  • Discuss treatment options for Diffuse Large B Cell Lymphoma based on cell of origin


The Tumor Board will focus on diffuse large B cell lymphoma and will include examination observations followed by imaging and laboratory results including flow cytometry and FISH. A discussion about the optimal treatment of double-hit and double-expressor lymphomas, based on clinical trial outcomes, will be discussed. The Tumor Board will also discuss the prediction of patient survival based on gene expression profiles.

Purchase the 2016 ASCO Tumor Boards Bundle to access to all 2016 ASCO Tumor Boards for added savings. Purchased separately, these items would be $180 altogether. When bundled, you save $55.

IMPORTANT NOTE: This course expires on December 14, 2019. Users must complete all necessary course components by this date.